{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:14:59Z","timestamp":1791645299579,"version":"4.3.4"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation","doi-asserted-by":"crossref","award":["82204460"],"award-info":[{"award-number":["82204460"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation","doi-asserted-by":"crossref","award":["82061148017"],"award-info":[{"award-number":["82061148017"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences","award":["2024-RC350-01"],"award-info":[{"award-number":["2024-RC350-01"]}]},{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin","doi-asserted-by":"crossref","award":["23JCQNJC01230"],"award-info":[{"award-number":["23JCQNJC01230"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin","doi-asserted-by":"crossref","award":["24JCZDJC00120"],"award-info":[{"award-number":["24JCZDJC00120"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"crossref"}]},{"name":"State Key Laboratory of Advanced Medical Materials and Devices Research Grant","award":["YGSKL-JYY-2024-JK01"],"award-info":[{"award-number":["YGSKL-JYY-2024-JK01"]}]},{"name":"Fellowship of China Postdoctoral Science Foundation","award":["2021M702464"],"award-info":[{"award-number":["2021M702464"]}]},{"name":"Open Funds of State Key Laboratory of Oncology in South China","award":["HN2023-05"],"award-info":[{"award-number":["HN2023-05"]}]},{"name":"Young Elite Scientists Sponsorship Program","award":["2024-2026QNRC001"],"award-info":[{"award-number":["2024-2026QNRC001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-025-02422-7","type":"journal-article","created":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T10:13:08Z","timestamp":1755339188000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Jab1 regulates HRR mRNA stability to modulate PARP inhibitor sensitivity in triple-negative breast cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Xin","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengfan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaolu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenxing","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Nicot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois X.","family":"Claret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dexin","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,16]]},"reference":[{"key":"2422_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"2422_CR2","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","volume":"27","author":"JS Parker","year":"2009","unstructured":"Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27:1160\u20137.","journal-title":"J Clin Oncol"},{"key":"2422_CR3","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","volume":"397","author":"S Loibl","year":"2021","unstructured":"Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397:1750\u201369.","journal-title":"Lancet"},{"key":"2422_CR4","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","volume":"9","author":"AC Garrido-Castro","year":"2019","unstructured":"Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9:176\u201398.","journal-title":"Cancer Discov"},{"key":"2422_CR5","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429\u201334.","journal-title":"Clin Cancer Res"},{"key":"2422_CR6","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","volume":"396","author":"EA Mittendorf","year":"2020","unstructured":"Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, Koehler A, Sohn J, Iwata H, Telli ML, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020;396:1090\u2013100.","journal-title":"Lancet"},{"key":"2422_CR7","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Hegg R, Im SA, Shaw Wright G, et al. Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108\u201321.","journal-title":"N Engl J Med"},{"key":"2422_CR8","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396:1817\u201328.","journal-title":"Lancet"},{"key":"2422_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19:91\u2013113.","journal-title":"Nat Rev Clin Oncol"},{"key":"2422_CR10","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","volume":"35","author":"YZ Jiang","year":"2019","unstructured":"Jiang YZ, Ma D, Suo C, Shi J, Xue M, Hu X, Xiao Y, Yu KD, Liu YR, Yu Y, et al. Genomic and transcriptomic landscape of Triple-Negative breast cancers: subtypes and treatment strategies. Cancer Cell. 2019;35:428\u2013e440425.","journal-title":"Cancer Cell"},{"key":"2422_CR11","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/S1470-2045(17)30450-3","volume":"18","author":"SB Kim","year":"2017","unstructured":"Kim SB, Dent R, Im SA, Espie M, Blau S, Tan AR, Isakoff SJ, Oliveira M, Saura C, Wongchenko MJ, et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2017;18:1360\u201372.","journal-title":"Lancet Oncol"},{"key":"2422_CR12","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","volume":"22","author":"EP Winer","year":"2021","unstructured":"Winer EP, Lipatov O, Im SA, Goncalves A, Munoz-Couselo E, Lee KS, Schmid P, Tamura K, Testa L, Witzel I, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:499\u2013511.","journal-title":"Lancet Oncol"},{"key":"2422_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12943-023-01805-y","volume":"22","author":"F Ye","year":"2023","unstructured":"Ye F, Dewanjee S, Li Y, Jha NK, Chen ZS, Kumar A, Vishakha, Behl T, Jha SK, Tang H. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 2023;22:105.","journal-title":"Mol Cancer"},{"key":"2422_CR14","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12943-025-02355-1","volume":"24","author":"Y Zou","year":"2025","unstructured":"Zou Y, Zhang H, Chen P, Tang J, Yang S, Nicot C, Guan Z, Li X, Tang H. Clinical approaches to overcome PARP inhibitor resistance. Mol Cancer. 2025;24:156.","journal-title":"Mol Cancer"},{"key":"2422_CR15","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355:1152\u20138.","journal-title":"Science"},{"key":"2422_CR16","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s43018-023-00535-w","volume":"4","author":"X Sun","year":"2023","unstructured":"Sun X, Tang H, Chen Y, Chen Z, Hu Z, Cui Z, Tao Y, Yuan J, Fu Y, Zhuang Z, et al. Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer. Nat Cancer. 2023;4:716\u201333.","journal-title":"Nat Cancer"},{"key":"2422_CR17","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523\u201333.","journal-title":"N Engl J Med"},{"key":"2422_CR18","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton JK, Rugo HS, Ettl J, Hurvitz SA, Goncalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753\u201363.","journal-title":"N Engl J Med"},{"key":"2422_CR19","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1093\/annonc\/mdw209","volume":"27","author":"C Winter","year":"2016","unstructured":"Winter C, Nilsson MP, Olsson E, George AM, Chen Y, Kvist A, Torngren T, Vallon-Christersson J, Hegardt C, Hakkinen J, et al. Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic. Ann Oncol. 2016;27:1532\u20138.","journal-title":"Ann Oncol"},{"key":"2422_CR20","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1470-2045(22)00739-2","volume":"24","author":"E Rodler","year":"2023","unstructured":"Rodler E, Sharma P, Barlow WE, Gralow JR, Puhalla SL, Anders CK, Goldstein L, Tripathy D, Brown-Glaberman UA, Huynh TT, et al. Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2023;24:162\u201374.","journal-title":"Lancet Oncol"},{"key":"2422_CR21","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1001\/jamaoncol.2020.0007","volume":"6","author":"E Pohl-Rescigno","year":"2020","unstructured":"Pohl-Rescigno E, Hauke J, Loibl S, Mobus V, Denkert C, Fasching PA, Kayali M, Ernst C, Weber-Lassalle N, Hanusch C, et al. Association of germline variant status with therapy response in high-risk early-stage breast cancer: a secondary analysis of the GeparOcto randomized clinical trial. JAMA Oncol. 2020;6:744\u20138.","journal-title":"JAMA Oncol"},{"key":"2422_CR22","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/s43018-022-00439-1","volume":"3","author":"JJ Gruber","year":"2022","unstructured":"Gruber JJ, Afghahi A, Timms K, DeWees A, Gross W, Aushev VN, Wu HT, Balcioglu M, Sethi H, Scott D, et al. A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes. Nat Cancer. 2022;3:1181\u201391.","journal-title":"Nat Cancer"},{"key":"2422_CR23","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.1200\/JCO.20.02151","volume":"38","author":"NM Tung","year":"2020","unstructured":"Tung NM, Robson ME, Ventz S, Santa-Maria CA, Nanda R, Marcom PK, Shah PD, Ballinger TJ, Yang ES, Vinayak S, et al. TBCRC 048: phase II study of Olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J Clin Oncol. 2020;38:4274\u201382.","journal-title":"J Clin Oncol"},{"key":"2422_CR24","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","volume":"18","author":"MP Dias","year":"2021","unstructured":"Dias MP, Moser SC, Ganesan S, Jonkers J. Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat Rev Clin Oncol. 2021;18:773\u201391.","journal-title":"Nat Rev Clin Oncol"},{"key":"2422_CR25","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","volume":"12","author":"KA Gelmon","year":"2011","unstructured":"Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12:852\u201361.","journal-title":"Lancet Oncol"},{"key":"2422_CR26","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/j.annonc.2020.09.017","volume":"31","author":"PG Pilie","year":"2020","unstructured":"Pilie PG, George A, Yap TA. Patient selection biomarker strategies for PARP inhibitor therapy. Ann Oncol. 2020;31:1603\u20135.","journal-title":"Ann Oncol"},{"key":"2422_CR27","doi-asserted-by":"publisher","first-page":"eadg7740","DOI":"10.1126\/scitranslmed.adg7740","volume":"16","author":"JH Ding","year":"2024","unstructured":"Ding JH, Xiao Y, Yang F, Song XQ, Xu Y, Ding XH, Ding R, Shao ZM, Di GH, Jiang YZ. Guanosine diphosphate-mannose suppresses homologous recombination repair and potentiates antitumor immunity in triple-negative breast cancer. Sci Transl Med. 2024;16:eadg7740.","journal-title":"Sci Transl Med"},{"key":"2422_CR28","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/383453a0","volume":"383","author":"FX Claret","year":"1996","unstructured":"Claret FX, Hibi M, Dhut S, Toda T, Karin M. A new group of conserved coactivators that increase the specificity of AP-1 transcription factors. Nature. 1996;383:453\u20137.","journal-title":"Nature"},{"key":"2422_CR29","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1073\/pnas.1209345110","volume":"110","author":"A Echalier","year":"2013","unstructured":"Echalier A, Pan Y, Birol M, Tavernier N, Pintard L, Hoh F, Ebel C, Galophe N, Claret FX, Dumas C. Insights into the regulation of the human COP9 signalosome catalytic subunit, CSN5\/Jab1. Proc Natl Acad Sci U S A. 2013;110:1273\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2422_CR30","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/embor.2009.33","volume":"10","author":"DA Chamovitz","year":"2009","unstructured":"Chamovitz DA. Revisiting the COP9 signalosome as a transcriptional regulator. EMBO Rep. 2009;10:352\u20138.","journal-title":"EMBO Rep"},{"key":"2422_CR31","doi-asserted-by":"publisher","first-page":"6125","DOI":"10.1038\/onc.2010.345","volume":"29","author":"L Tian","year":"2010","unstructured":"Tian L, Peng G, Parant JM, Leventaki V, Drakos E, Zhang Q, Parker-Thornburg J, Shackleford TJ, Dai H, Lin SY, et al. Essential roles of Jab1 in cell survival, spontaneous DNA damage and DNA repair. Oncogene. 2010;29:6125\u201337.","journal-title":"Oncogene"},{"key":"2422_CR32","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/hep.28372","volume":"63","author":"H Guo","year":"2016","unstructured":"Guo H, Jing L, Cheng Y, Atsaves V, Lv Y, Wu T, Su R, Zhang Y, Zhang R, Liu W, et al. Down-regulation of the cyclin-dependent kinase inhibitor p57 is mediated by Jab1\/Csn5 in hepatocarcinogenesis. Hepatology. 2016;63:898\u2013913.","journal-title":"Hepatology"},{"key":"2422_CR33","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1158\/0008-5472.CAN-11-3472","volume":"72","author":"Y Pan","year":"2012","unstructured":"Pan Y, Zhang Q, Tian L, Wang X, Fan X, Zhang H, Claret FX, Yang H. Jab1\/CSN5 negatively regulates p27 and plays a role in the pathogenesis of nasopharyngeal carcinoma. Cancer Res. 2012;72:1890\u2013900.","journal-title":"Cancer Res"},{"key":"2422_CR34","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.ccell.2016.10.010","volume":"30","author":"SO Lim","year":"2016","unstructured":"Lim SO, Li CW, Xia W, Cha JH, Chan LC, Wu Y, Chang SS, Lin WC, Hsu JM, Hsu YH, et al. Deubiquitination and stabilization of PD-L1 by CSN5. Cancer Cell. 2016;30:925\u201339.","journal-title":"Cancer Cell"},{"key":"2422_CR35","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1038\/onc.2012.294","volume":"32","author":"Y Pan","year":"2013","unstructured":"Pan Y, Zhang Q, Atsaves V, Yang H, Claret FX. Suppression of Jab1\/CSN5 induces radio- and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways. Oncogene. 2013;32:2756\u201366.","journal-title":"Oncogene"},{"key":"2422_CR36","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41388-021-02118-4","volume":"41","author":"YZ Mazzu","year":"2022","unstructured":"Mazzu YZ, Liao YR, Nandakumar S, Jehane LE, Koche RP, Rajanala SH, Li R, Zhao H, Gerke TA, Chakraborty G, et al. Prognostic and therapeutic significance of COP9 signalosome subunit CSN5 in prostate cancer. Oncogene. 2022;41:671\u201382.","journal-title":"Oncogene"},{"key":"2422_CR37","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1186\/s13046-021-02176-2","volume":"40","author":"X Peng","year":"2021","unstructured":"Peng X, Zhang S, Jiao W, Zhong Z, Yang Y, Claret FX, Elkabets M, Wang F, Wang R, Zhong Y, et al. Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy. J Exp Clin Cancer Res. 2021;40:374.","journal-title":"J Exp Clin Cancer Res"},{"key":"2422_CR38","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.ccell.2022.10.012","volume":"40","author":"Z Zhou","year":"2022","unstructured":"Zhou Z, Chen MM, Luo Y, Mojumdar K, Peng X, Chen H, Kumar SV, Akbani R, Lu Y, Liang H. Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma. Cancer Cell. 2022;40:1324-e13401328.","journal-title":"Cancer Cell"},{"key":"2422_CR39","doi-asserted-by":"publisher","first-page":"e2205529","DOI":"10.1002\/advs.202205529","volume":"10","author":"X Peng","year":"2023","unstructured":"Peng X, Zhang S, Wang Y, Zhou Z, Yu Z, Zhong Z, Zhang L, Chen ZS, Claret FX, Elkabets M, et al. Stellettin B sensitizes glioblastoma to DNA-Damaging treatments by suppressing PI3K-Mediated homologous recombination repair. Adv Sci (Weinh). 2023;10:e2205529.","journal-title":"Adv Sci (Weinh)"},{"key":"2422_CR40","doi-asserted-by":"publisher","first-page":"e2307747","DOI":"10.1002\/advs.202307747","volume":"11","author":"X Peng","year":"2024","unstructured":"Peng X, Huang X, Zhang S, Zhang N, Huang S, Wang Y, Zhong Z, Zhu S, Gao H, Yu Z, et al. Sequential Inhibition of PARP and BET as a rational therapeutic strategy for glioblastoma. Adv Sci (Weinh). 2024;11:e2307747.","journal-title":"Adv Sci (Weinh)"},{"key":"2422_CR41","doi-asserted-by":"publisher","first-page":"4795","DOI":"10.1038\/s41467-022-32311-2","volume":"13","author":"J Zhong","year":"2022","unstructured":"Zhong J, Yang X, Chen J, He K, Gao X, Wu X, Zhang M, Zhou H, Xiao F, An L, et al. Circular EZH2-encoded EZH2-92aa mediates immune evasion in glioblastoma via inhibition of surface NKG2D ligands. Nat Commun. 2022;13:4795.","journal-title":"Nat Commun"},{"key":"2422_CR42","doi-asserted-by":"publisher","first-page":"e13606","DOI":"10.1111\/cpr.13606","volume":"57","author":"C Alberghina","year":"2024","unstructured":"Alberghina C, Torrisi F, D\u2019Aprile S, Longhitano L, Giallongo S, Scandura G, Mannino G, Mele S, Sabini MG, Cammarata FP, et al. Microglia and glioblastoma heterocellular interplay sustains tumour growth and proliferation as an off-target effect of radiotherapy. Cell Prolif. 2024;57:e13606.","journal-title":"Cell Prolif"},{"key":"2422_CR43","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41467-017-02280-y","volume":"9","author":"CY Liu","year":"2018","unstructured":"Liu CY, Zhang YH, Li RB, Zhou LY, An T, Zhang RC, Zhai M, Huang Y, Yan KW, Dong YH, et al. LncRNA CAIF inhibits autophagy and attenuates myocardial infarction by blocking p53-mediated myocardin transcription. Nat Commun. 2018;9:29.","journal-title":"Nat Commun"},{"key":"2422_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0656-7","volume":"11","author":"M Zhang","year":"2018","unstructured":"Zhang M, Weng W, Zhang Q, Wu Y, Ni S, Tan C, Xu M, Sun H, Liu C, Wei P, Du X. The lncrna NEAT1 activates Wnt\/beta-catenin signaling and promotes colorectal cancer progression via interacting with DDX5. J Hematol Oncol. 2018;11: 113.","journal-title":"J Hematol Oncol"},{"key":"2422_CR45","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41467-020-20379-7","volume":"12","author":"R Fang","year":"2021","unstructured":"Fang R, Chen X, Zhang S, Shi H, Ye Y, Shi H, Zou Z, Li P, Guo Q, Ma L, et al. EGFR\/SRC\/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma. Nat Commun. 2021;12:177.","journal-title":"Nat Commun"},{"key":"2422_CR46","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12943-023-01847-2","volume":"22","author":"Z Zhao","year":"2023","unstructured":"Zhao Z, Yang W, Kong R, Zhang Y, Li L, Song Z, Chen H, Luo Y, Zhang T, Cheng C, et al. circEIF3I facilitates the recruitment of SMAD3 to early endosomes to promote TGF-beta signalling pathway-mediated activation of MMPs in pancreatic cancer. Mol Cancer. 2023;22:152.","journal-title":"Mol Cancer"},{"key":"2422_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111256","volume":"40","author":"S Cortellino","year":"2022","unstructured":"Cortellino S, Raveane A, Chiodoni C, Delfanti G, Pisati F, Spagnolo V, Visco E, Fragale G, Ferrante F, Magni S, et al. Fasting renders immunotherapy effective against low-immunogenic breast cancer while reducing side effects. Cell Rep. 2022;40: 111256.","journal-title":"Cell Rep"},{"key":"2422_CR48","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/s41419-021-03805-6","volume":"12","author":"S Zhang","year":"2021","unstructured":"Zhang S, Peng X, Li X, Liu H, Zhao B, Elkabets M, Liu Y, Wang W, Wang R, Zhong Y, Kong D. BKM120 sensitizes glioblastoma to the PARP inhibitor Rucaparib by suppressing homologous recombination repair. Cell Death Dis. 2021;12:546.","journal-title":"Cell Death Dis"},{"key":"2422_CR49","doi-asserted-by":"publisher","first-page":"8089","DOI":"10.1073\/pnas.0702108104","volume":"104","author":"S Busch","year":"2007","unstructured":"Busch S, Schwier EU, Nahlik K, Bayram O, Helmstaedt K, Draht OW, Krappmann S, Valerius O, Lipscomb WN, Braus GH. An eight-subunit COP9 signalosome with an intact JAMM motif is required for fungal fruit body formation. Proc Natl Acad Sci U S A. 2007;104:8089\u201394.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2422_CR50","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.cell.2008.07.022","volume":"134","author":"DM Duda","year":"2008","unstructured":"Duda DM, Borg LA, Scott DC, Hunt HW, Hammel M, Schulman BA. Structural insights into NEDD8 activation of cullin-RING ligases: conformational control of conjugation. Cell. 2008;134:995\u20131006.","journal-title":"Cell"},{"key":"2422_CR51","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrm.2015.15","volume":"17","author":"C Kilchert","year":"2016","unstructured":"Kilchert C, Wittmann S, Vasiljeva L. The regulation and functions of the nuclear RNA exosome complex. Nat Rev Mol Cell Biol. 2016;17:227\u201339.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2422_CR52","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.cell.2019.09.005","volume":"179","author":"MR Puno","year":"2019","unstructured":"Puno MR, Weick EM, Das M, Lima CD. SnapShot: the RNA exosome. Cell. 2019;179:282-e282281.","journal-title":"Cell"},{"key":"2422_CR53","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1097\/HEP.0000000000000711","volume":"80","author":"L Zhang","year":"2024","unstructured":"Zhang L, Jiao K, Liu Y, Xu G, Yang Z, Xiang L, Chen Z, Xu C, Zuo Y, Wu Z, et al. UBXN9 inhibits the RNA exosome function to promote T cell control of liver tumorigenesis. Hepatology. 2024;80:1041\u201357.","journal-title":"Hepatology"},{"key":"2422_CR54","doi-asserted-by":"publisher","first-page":"13166","DOI":"10.1038\/ncomms13166","volume":"7","author":"A Schlierf","year":"2016","unstructured":"Schlierf A, Altmann E, Quancard J, Jefferson AB, Assenberg R, Renatus M, Jones M, Hassiepen U, Schaefer M, Kiffe M, et al. Targeted inhibition of the COP9 signalosome for treatment of cancer. Nat Commun. 2016;7:13166.","journal-title":"Nat Commun"},{"key":"2422_CR55","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1038\/s41467-020-16142-7","volume":"11","author":"N Chopra","year":"2020","unstructured":"Chopra N, Tovey H, Pearson A, Cutts R, Toms C, Proszek P, Hubank M, Dowsett M, Dodson A, Daley F, et al. Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer. Nat Commun. 2020;11:2662.","journal-title":"Nat Commun"},{"issue":"2","key":"2422_CR56","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.annonc.2020.11.009","volume":"32","author":"HP Eikesdal","year":"2021","unstructured":"Eikesdal HP, Yndestad S, Elzawahry A, Llop-Guevara A, Gilje B, Blix ES, Espelid H, Lundgren S, Geisler J, Vagstad G, et al. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. Ann Oncol. 2021;32(2):240\u20139.","journal-title":"Ann Oncol"},{"key":"2422_CR57","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s43018-020-00148-7","volume":"2","author":"AK Mehta","year":"2021","unstructured":"Mehta AK, Cheney EM, Hartl CA, Pantelidou C, Oliwa M, Castrillon JA, Lin JR, Hurst KE, de Oliveira Taveira M, Johnson NT, et al. Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. Nat Cancer. 2021;2:66\u201382.","journal-title":"Nat Cancer"},{"key":"2422_CR58","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1038\/s41467-018-05031-9","volume":"9","author":"J Michelena","year":"2018","unstructured":"Michelena J, Lezaja A, Teloni F, Schmid T, Imhof R, Altmeyer M. Analysis of PARP inhibitor toxicity by multidimensional fluorescence microscopy reveals mechanisms of sensitivity and resistance. Nat Commun. 2018;9:2678.","journal-title":"Nat Commun"},{"key":"2422_CR59","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.trecan.2021.08.007","volume":"7","author":"K Fugger","year":"2021","unstructured":"Fugger K, Hewitt G, West SC, Boulton SJ. Tackling PARP inhibitor resistance. Trends Cancer. 2021;7:1102\u201318.","journal-title":"Trends Cancer"},{"key":"2422_CR60","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.1158\/1078-0432.CCR-07-5040","volume":"14","author":"MC Hsu","year":"2008","unstructured":"Hsu MC, Huang CC, Chang HC, Hu TH, Hung WC. Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptorgamma ligands in vitro and in vivo. Clin Cancer Res. 2008;14:4045\u201352.","journal-title":"Clin Cancer Res"},{"key":"2422_CR61","doi-asserted-by":"publisher","first-page":"8581","DOI":"10.1158\/0008-5472.CAN-06-0975","volume":"66","author":"MA Kouvaraki","year":"2006","unstructured":"Kouvaraki MA, Korapati AL, Rassidakis GZ, Tian L, Zhang Q, Chiao P, Ho L, Evans DB, Claret FX. Potential role of Jun activation domain-binding protein 1 as a negative regulator of p27kip1 in pancreatic adenocarcinoma. Cancer Res. 2006;66:8581\u20139.","journal-title":"Cancer Res"},{"key":"2422_CR62","first-page":"4130","volume":"7","author":"L Sui","year":"2001","unstructured":"Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K, Tai Y, Tokuda M. Jab1 expression is associated with inverse expression of p27(kip1) and poor prognosis in epithelial ovarian tumors. Clin Cancer Res. 2001;7:4130\u20135.","journal-title":"Clin Cancer Res"},{"key":"2422_CR63","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1182\/blood-2004-04-1242","volume":"105","author":"K Tomoda","year":"2005","unstructured":"Tomoda K, Kato JY, Tatsumi E, Takahashi T, Matsuo Y, Yoneda-Kato N. The Jab1\/COP9 signalosome subcomplex is a downstream mediator of Bcr-Abl kinase activity and facilitates cell-cycle progression. Blood. 2005;105:775\u201383.","journal-title":"Blood"},{"key":"2422_CR64","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.canlet.2012.07.033","volume":"326","author":"Y Pan","year":"2012","unstructured":"Pan Y, Claret FX. Targeting Jab1\/CSN5 in nasopharyngeal carcinoma. Cancer Lett. 2012;326:155\u201360.","journal-title":"Cancer Lett"},{"key":"2422_CR65","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1126\/science.1075901","volume":"298","author":"GA Cope","year":"2002","unstructured":"Cope GA, Suh GS, Aravind L, Schwarz SE, Zipursky SL, Koonin EV, Deshaies RJ. Role of predicted metalloprotease motif of Jab1\/Csn5 in cleavage of Nedd8 from Cul1. Sci. 2002;298:608\u201311.","journal-title":"Sci"},{"key":"2422_CR66","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1074\/jbc.C100442200","volume":"277","author":"MK Bae","year":"2002","unstructured":"Bae MK, Ahn MY, Jeong JW, Bae MH, Lee YM, Bae SK, Park JW, Kim KR, Kim KW. Jab1 interacts directly with HIF-1alpha and regulates its stability. J Biol Chem. 2002;277:9\u201312.","journal-title":"J Biol Chem"},{"key":"2422_CR67","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ccell.2019.09.004","volume":"36","author":"V Quereda","year":"2019","unstructured":"Quereda V, Bayle S, Vena F, Frydman SM, Monastyrskyi A, Roush WR, Duckett DR. Therapeutic targeting of CDK12\/CDK13 in triple-negative breast cancer. Cancer Cell. 2019;36:545-e558547.","journal-title":"Cancer Cell"},{"key":"2422_CR68","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/ncb1061","volume":"5","author":"LA Higa","year":"2003","unstructured":"Higa LA, Mihaylov IS, Banks DP, Zheng J, Zhang H. Radiation-mediated proteolysis of CDT1 by CUL4-ROC1 and CSN complexes constitutes a new checkpoint. Nat Cell Biol. 2003;5:1008\u201315.","journal-title":"Nat Cell Biol"},{"key":"2422_CR69","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S0092-8674(03)00316-7","volume":"113","author":"R Groisman","year":"2003","unstructured":"Groisman R, Polanowska J, Kuraoka I, Sawada J, Saijo M, Drapkin R, Kisselev AF, Tanaka K, Nakatani Y. The ubiquitin ligase activity in the DDB2 and CSA complexes is differentially regulated by the COP9 signalosome in response to DNA damage. Cell. 2003;113:357\u201367.","journal-title":"Cell"},{"key":"2422_CR70","doi-asserted-by":"publisher","first-page":"26316","DOI":"10.1074\/jbc.M910306199","volume":"275","author":"K Tanaka","year":"2000","unstructured":"Tanaka K, Hiramoto T, Fukuda T, Miyagawa K. A novel human rad54 homologue, Rad54B, associates with Rad51. J Biol Chem. 2000;275:26316\u201321.","journal-title":"J Biol Chem"},{"key":"2422_CR71","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/emboj\/21.1.175","volume":"21","author":"K Miyagawa","year":"2002","unstructured":"Miyagawa K, Tsuruga T, Kinomura A, Usui K, Katsura M, Tashiro S, Mishima H, Tanaka K. A role for RAD54B in homologous recombination in human cells. EMBO J. 2002;21:175\u201380.","journal-title":"EMBO J"},{"key":"2422_CR72","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nrc3743","volume":"14","author":"A Losada","year":"2014","unstructured":"Losada A. Cohesin in cancer: chromosome segregation and beyond. Nat Rev Cancer. 2014;14:389\u201393.","journal-title":"Nat Rev Cancer"},{"key":"2422_CR73","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1158\/0008-5472.CAN-17-1494","volume":"78","author":"JPW Carey","year":"2018","unstructured":"Carey JPW, Karakas C, Bui T, Chen X, Vijayaraghavan S, Zhao Y, Wang J, Mikule K, Litton JK, Hunt KK, Keyomarsi K. Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple-negative breast cancer. Cancer Res. 2018;78:742\u201357.","journal-title":"Cancer Res"},{"key":"2422_CR74","doi-asserted-by":"publisher","unstructured":"Yang L, Zhang Y, Shan W, Hu Z, Yuan J, Pi J, Wang Y, Fan L, Tang Z, Li C, et al. Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition. Sci Transl Med. 2017;9:eaal1645. https:\/\/doi.org\/10.1126\/scitranslmed.aal1645.","DOI":"10.1126\/scitranslmed.aal1645"},{"key":"2422_CR75","doi-asserted-by":"publisher","unstructured":"Lu Z, Mao W, Yang H, Santiago-O\u2019Farrill JM, Rask PJ, Mondal J, Chen H, Ivan C, Liu X, Liu CG, et al. SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers. J Clin Invest. 2022;132:e146471. https:\/\/doi.org\/10.1172\/JCI146471.","DOI":"10.1172\/JCI146471"},{"key":"2422_CR76","doi-asserted-by":"publisher","first-page":"6321","DOI":"10.1093\/nar\/gkv592","volume":"43","author":"JW Ahn","year":"2015","unstructured":"Ahn JW, Kim S, Na W, Baek SJ, Kim JH, Min K, Yeom J, Kwak H, Jeong S, Lee C, et al. SERBP1 affects homologous recombination-mediated DNA repair by regulation of CtIP translation during S phase. Nucleic Acids Res. 2015;43:6321\u201333.","journal-title":"Nucleic Acids Res"},{"key":"2422_CR77","doi-asserted-by":"publisher","first-page":"101255","DOI":"10.1016\/j.xcrm.2023.101255","volume":"4","author":"DJ McGrail","year":"2023","unstructured":"McGrail DJ, Li Y, Smith RS, Feng B, Dai H, Hu L, Dennehey B, Awasthi S, Mendillo ML, Sood AK, et al. Widespread BRCA1\/2-independent homologous recombination defects are caused by alterations in RNA-binding proteins. Cell Rep Med. 2023;4:101255.","journal-title":"Cell Rep Med"},{"key":"2422_CR78","doi-asserted-by":"publisher","unstructured":"Iwai K, Nambu T, Kashima Y, Yu J, Eng K, Miyamoto K, Kakoi K, Gotou M, Takeuchi T, Kogame A, et al. A CDC7 inhibitor sensitizes DNA-damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recovery. Sci Adv. 2021;7:eabf0197. https:\/\/doi.org\/10.1126\/sciadv.abf0197.","DOI":"10.1126\/sciadv.abf0197"},{"key":"2422_CR79","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.molcel.2020.07.026","volume":"80","author":"T Reislander","year":"2020","unstructured":"Reislander T, Groelly FJ, Tarsounas M. DNA damage and cancer immunotherapy: a STING in the tale. Mol Cell. 2020;80:21\u20138.","journal-title":"Mol Cell"},{"key":"2422_CR80","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1158\/2159-8290.CD-18-1020","volume":"9","author":"T Sen","year":"2019","unstructured":"Sen T, Rodriguez BL, Chen L, Corte CMD, Morikawa N, Fujimoto J, Cristea S, Nguyen T, Diao L, Li L, et al. Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer. Cancer Discov. 2019;9:646\u201361.","journal-title":"Cancer Discov"},{"key":"2422_CR81","doi-asserted-by":"publisher","first-page":"100276","DOI":"10.1016\/j.xcrm.2021.100276","volume":"2","author":"T Qing","year":"2021","unstructured":"Qing T, Jun T, Lindblad KE, Lujambio A, Marczyk M, Pusztai L, Huang KL. Diverse immune response of DNA damage repair-deficient tumors. Cell Rep Med. 2021;2:100276.","journal-title":"Cell Rep Med"},{"key":"2422_CR82","doi-asserted-by":"publisher","first-page":"7430","DOI":"10.1038\/s41467-023-42850-x","volume":"14","author":"L Tao","year":"2023","unstructured":"Tao L, Zhou Y, Pan X, Luo Y, Qiu J, Zhou X, Chen Z, Li Y, Xu L, Zhou Y, et al. Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1\/2 and RAD51. Nat Commun. 2023;14:7430.","journal-title":"Nat Commun"},{"key":"2422_CR83","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/s41467-023-35880-y","volume":"14","author":"T Tsujino","year":"2023","unstructured":"Tsujino T, Takai T, Hinohara K, Gui F, Tsutsumi T, Bai X, Miao C, Feng C, Gui B, Sztupinszki Z, et al. CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer. Nat Commun. 2023;14:252.","journal-title":"Nat Commun"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02422-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02422-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02422-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T04:39:54Z","timestamp":1757392794000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-025-02422-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,16]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2422"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02422-7","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,16]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were carried out in accordance with the guidelines for the care and use of laboratory animals and approved by the Ethical Committee of Tianjin Medical University (protocol number: TMUaMEC 2023126; date of approval: April 20, 2023).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"217"}}